The server is under maintenance between 08:00 to 12:00 (GMT+08:00), and please visit later.
We apologize for any inconvenience caused
Login  | Sign Up  |  Oriprobe Inc. Feed
China/Asia On Demand
Journal Articles
Laws/Policies/Regulations
Companies/Products
Bookmark and Share
Clinical study of Thalidomide combined with CIK cells on the treatment of lymphoma
Author(s): 
Pages: 734-736
Year: Issue:  12
Journal: Qilu Pharmaceutical Affairs

Keyword:  ThalidomideCytokine - induced killer cellsLymphama;
Abstract: Objective To evaluate the effectiveness and security of cytokine - induced killer cells′ cure on B - cell lymphoma. Methods 64 cases of lymphoma patients in hospital from Jan. 2011 to Jan. 2014 were selected and divided into observation group(32 patients)and control group(32 patients)randomly. The observation group was treated by Thalido-mide combined with CIK cells,while control group by CIK cells. The treatment effects,adverse reactions of two groups were recorded and compared. Results Adverse reaction was not occurred in two groups. The levels of beta - 2 - microglobulin and LDH were reduced remarkably,especially in the observation group. Clinical symptoms and living quality of all the pa-tients in both groups were improved. The total effective rates of observation group and control group were 84. 3% ,60%(P <0. 05),respectively. The PFS rates of observation group and control group in one year were 82. 3% ,62. 7%(P < 0. 05),re-spectively. The total survival rates of observation group and control group in one year were 96. 8% ,77. 4%(P < 0. 05),re-spectively. Conclusion Compared with CIK cells,Thalidomide showed a better performance in improving patient remission rate,extending patient survival without obvious toxic and side effects to be worth for a further research.
Related Articles
No related articles found